DNMT3A and hematopoietic and lymphoid system neoplasm: Although cumbersome, this approach led to the successful introduction of clinically relevant mutations in a variety of genes, including DNA methyltransferase 3 alpha (Dnmt3a) and tet methylcytosine dioxygenase 2 (Tet2), within HSPC, and their introduction to mice to establish blood cancer models.